Holen Sie sich die Stockscreener-App
15.83
0.75%
-0.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.95
Offen:
$16.06
24-Stunden-Volumen:
813.42K
Relative Volume:
0.74
Marktkapitalisierung:
$2.11B
Einnahmen:
$298.30M
Nettoeinkommen (Verlust:
$298.21M
KGV:
7.3162
EPS:
2.1637
Netto-Cashflow:
$166.93M
1W Leistung:
-3.71%
1M Leistung:
-2.82%
6M Leistung:
+1.41%
1J Leistung:
+40.59%
1-Tages-Spanne:
$15.74
$16.06
1-Wochen-Bereich:
$15.74
$16.62
52-Wochen-Spanne:
$10.90
$19.25
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
15.83 | 2.19B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | Hochstufung | Jefferies | Hold → Buy |
| 2025-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Discipline and Rules-Based Execution in AUPH Response - Stock Traders Daily
A look at a few stocks - Moomoo
Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside (AUPH) - Seeking Alpha
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Aurora Innovation stock reacts as Uber cuts its stake and Aurinia delivers strong Q2 figures - AD HOC NEWS
Aurinia Stock Jumps After Earnings Beat And Pipeline Progress - simplywall.st
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company - Yahoo Finance
Technical Reactions to AUPH Trends in Macro Strategies - Stock Traders Daily
Aurinia Pharmaceuticals (NASDAQ: AUPH) Chief Legal Officer Stephen P. Robertson Disposes 11,939 Shares at $15.95 on September 10, 2026 - kalkinemedia.com
Aurinia Pharmaceuticals' Chief Legal Officer Sells 11,939 Shares to Cover Tax Withholding on PSU Vesting - Kalkine Media
Tax-withholding stock sale by Aurinia Pharmaceuticals (AUPH) legal chief - Stock Titan
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
Aurinia Pharmaceuticals Stock Price Forecast. Should You Buy AUPH? - StockInvest.us
Responsive Playbooks and the AUPH Inflection - Stock Traders Daily
LB Pharmaceuticals Names Joseph M. Miller as CFO, Details Compensation and Severance Package - kalkinemedia.com
LB Pharmaceuticals Inc Announces Appointment of Joseph M. Miller to Chief Financial Officer, Effective September 2, 2026 - marketscreener.com
A finance executive who helped launch a lupus drug joins LB Pharmaceuticals - Stock Titan
Is Aurinia Pharmaceuticals (AUPH) Still Below Fair Value After A 60% Rise? - simplywall.st
Kezar Life Sciences stock in focus after Aurinia tender offer and merger terms surface - AD HOC NEWS
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)? - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) Peer Comparison – Compare with Others - Value Research
Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock - Benzinga
ILJIN group pushes Aurinia (NASDAQ: AUPH) stake under 5% after share sales - Stock Titan
Aurinia (NASDAQ: AUPH) legal chief sells shares to cover taxes - stocktitan.net
Aurinia (AUPH) Quarterly Results: EPS Clears the Reported Estimate at the Close; Market Response: The Share Price Sheds 0.48% in the Available RecordGuidance Update - vinanet.vn
Aurinia (AUPH) Market: Falls 3.59% to $16.65 at the Close; Technical Setup: $15.82 and $17.48 Define the Nearby Reference Levels on the DayBuyback Factor - siam.in
Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes - Stock Titan
Teva and Aurinia settle generics dispute over lupus drug, voclosporin - Life Sciences IP Review
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement - finance.biggo.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - Yahoo Finance UK
Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21 - Moomoo
AUPH Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Benzinga
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain - Yahoo Finance
Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules - Kalkine Media
AUPH Stock Rallies 6% After-Hours — Here’s Why - Stocktwits
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours - marketscreener.com
Aurinia settles patent dispute with Teva over generic drug By Investing.com - Investing.com Canada
Aurinia stock falls on Teva patent settlement for voclosporin By Investing.com - Investing.com Australia
Aurinia, Teva Reach Voclosporin Patent Litigation Settlement - TipRanks
Aurinia stock falls on Teva patent settlement for voclosporin - Investing.com
Aurinia settles patent dispute with Teva over generic drug - Investing.com
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Robertson Stephen P. | Chief Legal Officer |
Aug 21 '26 |
Sale |
16.97 |
20,975 |
355,946 |
600,787 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):